186
Participants
Start Date
January 28, 2019
Primary Completion Date
October 31, 2023
Study Completion Date
October 31, 2023
Rucaparib
PARP inhibitor
Abemaciclib
CDK4/6 inhibitor
pembrolizumab & bemcentinib
PD1 checkpoint inhibitor, AXL inhibitor
Atezolizumab & Bevacizumab
PDL1 checkpoint inhibitor, VEGF inhibitor
Dostarlimab and Niraparib
IG Antibody, PARP Inhibitor
University Hospitals of Leicester NHS Trust, Leicester
Collaborators (3)
British Lung Foundation
OTHER
Clovis Oncology, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
BerGenBio ASA
INDUSTRY
Roche Pharma AG
INDUSTRY
University Hospitals, Leicester
OTHER
The Christie NHS Foundation Trust
OTHER
GlaxoSmithKline
INDUSTRY
University of Leicester
OTHER